» Articles » PMID: 38712813

Comprehensive Understanding of Glioblastoma Molecular Phenotypes: Classification, Characteristics, and Transition

Overview
Journal Cancer Biol Med
Specialty Oncology
Date 2024 May 7
PMID 38712813
Authors
Affiliations
Soon will be listed here.
Abstract

Among central nervous system-associated malignancies, glioblastoma (GBM) is the most common and has the highest mortality rate. The high heterogeneity of GBM cell types and the complex tumor microenvironment frequently lead to tumor recurrence and sudden relapse in patients treated with temozolomide. In precision medicine, research on GBM treatment is increasingly focusing on molecular subtyping to precisely characterize the cellular and molecular heterogeneity, as well as the refractory nature of GBM toward therapy. Deep understanding of the different molecular expression patterns of GBM subtypes is critical. Researchers have recently proposed tetra fractional or tripartite methods for detecting GBM molecular subtypes. The various molecular subtypes of GBM show significant differences in gene expression patterns and biological behaviors. These subtypes also exhibit high plasticity in their regulatory pathways, oncogene expression, tumor microenvironment alterations, and differential responses to standard therapy. Herein, we summarize the current molecular typing scheme of GBM and the major molecular/genetic characteristics of each subtype. Furthermore, we review the mesenchymal transition mechanisms of GBM under various regulators.

Citing Articles

Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.

DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R Front Cell Dev Biol. 2025; 13:1535073.

PMID: 40078366 PMC: 11897528. DOI: 10.3389/fcell.2025.1535073.


Sesquiterpene Lactones as Promising Anti-Glioblastoma Drug Candidates Exerting Complex Effects on Glioblastoma Cell Viability and Proneural-Mesenchymal Transition.

Markov A, Moralev A, Odarenko K Biomedicines. 2025; 13(1).

PMID: 39857717 PMC: 11761231. DOI: 10.3390/biomedicines13010133.


Bullatine A suppresses glioma cell growth by targeting SIRT6.

Wang Z, Zhu Y, Luo C, Zhang F, Zhao J, Fu C Heliyon. 2025; 11(1):e41440.

PMID: 39845013 PMC: 11750491. DOI: 10.1016/j.heliyon.2024.e41440.


Comprehensive Bioinformatics Analysis Reveals the Potential Role of the hsa_circ_0001081/miR-26b-5p Axis in Regulating COL15A1 and TRIB3 within Hypoxia-Induced miRNA/mRNA Networks in Glioblastoma Cells.

Lenda B, Zebrowska-Nawrocka M, Balcerczak E Biomedicines. 2024; 12(10).

PMID: 39457549 PMC: 11504030. DOI: 10.3390/biomedicines12102236.


Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma.

Rahman M, Ali M Cancers (Basel). 2024; 16(17).

PMID: 39272834 PMC: 11394361. DOI: 10.3390/cancers16172975.

References
1.
Kaffes I, Szulzewsky F, Chen Z, Herting C, Gabanic B, Velazquez Vega J . Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncoimmunology. 2019; 8(11):e1655360. PMC: 6791439. DOI: 10.1080/2162402X.2019.1655360. View

2.
Yang M, Chen X, Zhang J, Xiong E, Wang Q, Fang W . ME2 Promotes Proneural-Mesenchymal Transition and Lipogenesis in Glioblastoma. Front Oncol. 2021; 11:715593. PMC: 8351415. DOI: 10.3389/fonc.2021.715593. View

3.
Gao Z, Xu J, Fan Y, Qi Y, Wang S, Zhao S . PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. J Exp Clin Cancer Res. 2022; 41(1):223. PMC: 9284800. DOI: 10.1186/s13046-022-02431-0. View

4.
Zhang C, Han X, Xu X, Zhou Z, Chen X, Tang Y . FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. Cell Death Dis. 2018; 9(5):469. PMC: 5920065. DOI: 10.1038/s41419-018-0482-4. View

5.
Cooper L, Gutman D, Chisolm C, Appin C, Kong J, Rong Y . The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012; 180(5):2108-19. PMC: 3354586. DOI: 10.1016/j.ajpath.2012.01.040. View